LOGIN  |  REGISTER
Amneal Pharmaceuticals
Chimerix

Vor to Participate in Two Upcoming Investor Conferences

November 08, 2021 | Last Trade: US$2.21 0.14 -5.96

Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vor’s Chief Financial Officer, will be participating in two upcoming virtual investor conferences:

Stifel 2021 Virtual Healthcare Conference
Fireside Chat Date: Monday, November 15, 2021
Time: 4:00 PM ET

Evercore ISI 4th Annual HealthCONx Virtual Conference
Fireside Chat Date: Thursday, December 2, 2021
Time: 10:55 AM ET

A live webcast of both fireside chats can be accessed via the Investors section of the Company's website at www.vorbio.com. An archived replay of each webcast will also be available.

About Vor Biopharma

Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contacts:

Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.


Assertio

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page